BEAM - BEAM

La vendita allo scoperto per Beam Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Beam Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Beam Therapeutics (NASDAQ:BEAM) Azioni, Report sulle vendite allo scoperto

Beam Therapeutics

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Beam Therapeutics Inc

Beam

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Communications Holdings Ltd

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

RBC Capital analyst Luca Issi reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Sector Perform and maintains $27 price target.

News

Price Target

Reiteration

Analyst Ratings

BEAM

RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target

Jones Trading analyst Soumit Roy initiates coverage on Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Hold rating.

Initiation

Jones Trading Initiates Coverage On Beam Therapeutics with Hold Rating

In the latest quarter, 6 analysts provided ratings for Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.83, a high estimate of $80.00, and a low estimate of $27.00. This upward trend is evident, with the current average reflecting a 11.22% increase from the previous average price target of $50.20.
<img src="https://www.benzinga.com/files/images/story/2024/1726056040_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Beam Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beam Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Beam Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Beam Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Beam Therapeutics</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Breaking Down Beam Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Beam Therapeutics faced challenges, resulting in a decline of approximately -41.48% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Beam Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -773.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Beam Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)

Stifel analyst Benjamin Burnett maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and raises the price target from $66 to $69.

Stifel Maintains Buy on Beam Therapeutics, Raises Price Target to $69

5 analysts have shared their evaluations of Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Beam Therapeutics, revealing an average target of $53.2, a high estimate of $80.00, and a low estimate of $27.00. Marking an increase of 15.03%, the current average surpasses the previous average price target of $46.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1724331608_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Beam Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Beam Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Beam Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Beam Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
<h2>Discovering Beam Therapeutics: A Closer Look</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Unraveling the Financial Story of Beam Therapeutics</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Beam Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -41.48%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Beam Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -773.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.95%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.19.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For Beam Therapeutics

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>), a private RNA editing company that went public via a reverse merger with&nbsp;Frequency Therapeutics Inc. in an all-stock&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33229914/why-are-frequency-therapeutics-shares-surging-today" rel="noreferrer noopener">merger transaction</a>.&nbsp;
The company&#8217;s proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform harnesses the body&#8217;s natural base editing system – specifically ADAR (Adenosine&nbsp;Deaminase&nbsp;Acting on&nbsp;RNA) – to make targeted edits to a single RNA base.
William Blair notes that ADAR editing permits chronic dosing and titratability of a genetic editing medicine without the risk of permanent off-target effects or potential issues with over- or underexpression of target genes.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36075434/why-newly-listed-korro-bio-shares-are-gaining-today" rel="noreferrer noopener">Why Newly Listed Korro Bio Shares Are Gaining Today?</a>
William Blair emphasizes that Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is set to release the first clinical data for an ADAR-recruiting therapy in 2024. The analyst initiates <a target="_blank" href="https://www.benzinga.com/quote/KRRO/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>.
The data from the Phase 1b/2a RestorAATion-2 trial of WVE-006 for severe Alpha-1 antitrypsin deficiency (A1ATD) will be crucial in determining whether the ADAR-mediated RNA editing mechanism is consistent across species—a key concern for investors due to differences in genetic homology.
Korro&#8217;s lead asset, KRRO-110, is a lipid nanoparticle (LNP)- encapsulated oligonucleotide designed to correct the E342K PiZ mutation in SERPINA1, which can lead to severe forms of alpha-1 antitrypsin deficiency (A1ATD).
The asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024, with interim proof-of-concept clinical data in 2025 and trial completion in 2026.
&#8220;We believe Korro&#8217;s preclinical data package, particularly in the NSG PiZ mouse model, is best-in-class for the ADAR field,&#8221; William Blair analyst writes.
&#8220;We also believe that Wave&#8217;s WVE-006 (GalNAc-conjugated ADAR-recruiting ASO) and Beam Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) BEAM-302 (base editing approach) clinical programs validate Korro&#8217;s approach but still leave clear room for differentiation on efficacy or specificity/safety,&#8221; the analyst adds.
Price Action: KRRO stock is up 8.64% at $39.50 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40373358/acelyrin-cuts-workforce-deprioritizes-former-lead-drug-izokibep" target="_blank" rel="noreferrer noopener">Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a> on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
Image via Shutterstock

Biotech

Health Care

Movers

General

KRRO

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

JP Morgan analyst Eric Joseph maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Overweight and raises the price target from $45 to $48.

JP Morgan Maintains Overweight on Beam Therapeutics, Raises Price Target to $48

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Equal-Weight and lowers the price target from $33 to $31.

Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $31

Guidance

Beam Therapeutics Says Ended Q2 2024 With $1.0B In Cash, Cash Equivalents And Marketable Securities; Expected Operating Runway Into 2027

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.25) by 11.2 percent. This is a 2.78 percent decrease over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $11.772 million which missed the analyst consensus estimate of $14.183 million by 17.00 percent. This is a 41.48 percent decrease over sales of $20.116 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Beam Therapeutics Q2 2024 GAAP EPS $(1.11) Beats $(1.25) Estimate, Sales $11.772M Miss $14.183M Estimate

These six mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares jumped 47.88% as the company successfully completed its <a href="https://www.benzinga.com//node/39958682" target="_blank" rel="noreferrer noopener">first five commercial satellites</a>.</li>
<li>Goosehead Insurance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) stock upped 39.86% following <a href="https://www.benzinga.com//node/39941916" target="_blank" rel="noreferrer noopener">upbeat second-quarter results</a>.</li>
<li>ViaSat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) shares escalated by 30.78%. The company announced a <a href="https://www.benzinga.com//node/39973735" target="_blank" rel="noreferrer noopener">new reporting segment structure</a>.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares grew 29.86% after the company announced the <a href="https://www.benzinga.com//node/39966690" target="_blank" rel="noreferrer noopener">advancement of VK2735 to Phase 3</a>.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) stock increased 23.93% after HC Wainwright initiated coverage on the stock with a Buy rating and announced <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings" target="_blank" rel="noreferrer noopener">an $80 price target</a>.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) shares rose 19.72%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40001614/universal-health-services-lockheed-martin-were-among-top-11-large-cap-stocks-that-shined-the-brighte" target="_blank" rel="noreferrer noopener">Universal Health Services &amp; Lockheed Martin Were Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/07/40001668/ford-stellantis-and-dell-are-among-top-12-large-cap-losers-last-week-july-21-july-27-are-the-other" target="_blank" rel="noreferrer noopener">Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via AST SpaceMobile

Mid Cap

ASTS

CLDX

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

PEGA

PTGX

VKTX

VSAT

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?

U.S. stocks were higher, with the Dow Jones index gaining more than 1% on Thursday.
Shares of International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) rose during Thursday's session following strong <a href="https://www.benzinga.com/news/24/07/39961144/why-ibm-stock-is-trading-higher-on-thursday">quarterly earnings</a>.
IBM reported quarterly earnings of $2.43 per share, which beat the analyst consensus estimate of $2.19. Quarterly sales clocked in at $15.8 billion, which beat the analyst consensus estimate of $15.616 billion.
IBM shares gained 6.4% to $195.75 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares surged 28.2% to $64.64 after the company reported better-than-expected second-quarter EPS results.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) jumped 25.2% to $16.72. The company announced the successful completion of its first five commercial satellites.</li>
<li>Bally&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) shares rose 24.2% to $16.80. Bally&#8217;s entered into merger agreement with affiliates of Standard General L.P.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 18.3% to $341.39 following better-than-expected quarterly earnings.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) jumped 16.3% to $141.59 after the company reported better-than-expected quarterly financial results.</li>
<li>RPC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) rose 15.1% to $6.64 following upbeat earnings.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) rose 13.7% to $831.97 after the company reported better-than-expected second-quarter financial results.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) jumped 13.6% to $19.05.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 13.1% to $69.09 after the company reported better-than-expected second-quarter financial results.</li>
<li>Helmerich &amp; Payne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) gained 12.5% to $42.46 following third-quarter results.</li>
<li>CBRE Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) surged 11.7% to $109.87 after the company raised its 2024 guidance.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) climbed 11.1% to $300.96 following upbeat earnings.</li>
<li>Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) rose 11% to $48.08 following better-than-expected quarterly earnings.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 10.7% to $571.01 after the company reported better-than-expected quarterly adjusted EPS and sales.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) gained 10.5% to $128.36 following upbeat earnings.</li>
<li>Transocean Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) surged 10.2% to $5.80.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) rose 10.1% to $32.81.</li>
<li>Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) gained 10.1% to $53.92 following second-quarter results.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) shares climbed 9.6% to $565.64 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Mr. Cooper Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>) gained 9.5% to $94.86 following second-quarter results.</li>
<li>RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) climbed 9.2% to $121.14 after the company reported better-than-expected quarterly earnings.</li>
<li>Oceaneering International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) rose 9.2% to $27.79 following strong sales.</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) gained 8.1% to $76.27 after the company reported better-than-expected second-quarter earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) rose 8.1% to $201.00 after the company reported better-than-expected second-quarter earnings and increased FY 2024 guidance.</li>
<li>RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) climbed 8% to $113.24 following a second-quarter earnings beat.</li>
<li>Morningstar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) rose 7.8% to $328.71. The company reported second-quarter financial results yesterday.</li>
<li>Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) gained 7.4% to $67.36 after the company reported better-than-expected second-quarter financial results.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) rose 7.4% to $262.60.</li>
<li>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) shares rose 6.1% to $173.75.</li>
<li>Unilever PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>) gained 5.9% to $59.90 following HI results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39961795/apple-to-rally-around-10-here-are-10-top-analyst-forecasts-for-thursday">Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

BALY

CBRE

COOP

JBHT

MORN

NDAQ

PLXS

IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday.
Shares of Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39907956/life-science-giant-danahers-q2-earnings-beat-estimates-on-sustained-positive-momentum-in-bioprocess">second quarter earnings</a>.
Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Danaher shares gained 7.4% to $269.35 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) shares jumped 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) surged 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 11.8% to $6.90.</li>
<li>KKR Real Estate Finance Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) surged 11.2% to $11.22 following second-quarter results.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) shares jumped 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 10.3% to $66.27.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 9% to $29.48. HC Wainwright &amp; Co. analyst Patrick Trucchio initiated coverage on Beam Therapeutics with a Buy rating and announced a price target of $80.</li>
<li>Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) rose 8.5% to $28.11 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) gained 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) climbed 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Inter Parfums, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) gained 8% to $137.34 after the company reported better-than-expected expected sales.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) rose 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares gained 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) gained 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Park National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRK#NYSE">PRK</a>) gained 7.4% to $182.78 following upbeat quarterly earnings.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) gained 7.1% to $3.46.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) shares surged 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) gained 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Hims &amp; Hers Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NASDAQ">HIMS</a>) gained 5.6% to $21.51.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) surged 5.5% to $178.95.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) rose 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) gained 5.2% to $97.99 following upbeat quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907046/best-buy-kroger-and-2-other-stocks-insiders-are-selling">Best Buy, Kroger And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

IPAR

IRDM

KNSA

KREF

MESO

MMYT

MSCI

SPOT

ZION

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

WIIM

Beam Therapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced an $80 price target.

HC Wainwright &amp; Co. analyst Patrick Trucchio initiates coverage on Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy rating and announces Price Target of $80.

HC Wainwright & Co. Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $80

On Thursday, Cathie Wood&#8217;s Ark Invest made a significant move by reducing its stake in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), despite a recent bullish outlook on the company&#8217;s potential in the autonomous taxi sector.
The Tesla Trade
The ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) sold 32,199 shares of Tesla, valued at approximately $8.02 million based on the closing price of $249.23 on the same day. This move comes after recent comments by Wood, who expressed her belief that Tesla&#8217;s stock could see a significant surge as it moves into the autonomous taxi business.
Wood, in a recent Tiger Money podcast, stated that Tesla could <a href="https://www.benzinga.com/news/24/07/39807403/tesla-stock-could-shoot-up-10-times-due-to-robotaxis-says-cathie-wood-the-biggest-ai-project-evolvin">potentially capture</a> up to 50% of the autonomous taxi market, presenting a global revenue opportunity of $8 trillion to $10 trillion. She further emphasized that &#8220;Autonomous taxi platforms are the biggest AI project evolving today.&#8221;
However, this isn&#8217;t the first time Ark Invest has trimmed its Tesla holdings. Earlier in July, Ark Invest began selling Tesla shares just after the company reported second-quarter deliveries that topped muted forecasts. The firm <a href="https://www.benzinga.com/markets/equities/24/07/39684695/cathie-woods-ark-pauses-tesla-selling-after-trimming-stake-for-3-straight-sessions-whats-going-o">continued selling</a> a smattering of its Tesla holdings over the next two sessions before pausing on last Monday.
Other Key Trades:
<ul>
<li>Ark Invest&#8217;s Genomic Revolution ETF (ARKG) bought shares of Guardant Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>). The same fund also acquired shares of 10X Genomics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>). </li>
<li>Both ARKG and the flagship Ark Innovation ETF (ARKK) purchased shares of Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>). </li>
<li>The ARKW fund also bought shares of GitLab Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>).</li>
</ul>
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/news/24/07/39811211/as-billionaire-boys-go-all-in-for-trump-anthony-scaramucci-has-word-of-caution-tonic-they-are-prescr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">As &#8216;Billionaire Boys&#8217; Go All In For Trump, Anthony Scaramucci Has Word Of Caution: &#8216;Tonic They Are Prescribing Will Be Bad For America And The World&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

ETFs

ARKW

GTLB

TSLA

Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast

Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.

Management

Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase

Beam Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beam#NASDAQ">BEAM</a>) is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease, an inherited blood disorder.
BEAM&#39;s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases.
Here are some reasons why investors should consider betting on Beam Therapeutics stock.
Good Rank and Rising Estimates: Beam Therapeutics currently has a Zacks Rank #2 (Buy).
In the past 90 days, the estimate for Beam Therapeutics&#39; 2024 loss per share has narrowed from $5.53 to $4.68. During the same period, loss per share estimate for 2025 has narrowed from $5.04 to $4.66.
Hematology Program Picking Up Pace: The company is pursuing an ex vivo, autologous transplant-based approach for SCD and beta-thalassemia. It is currently developing BEAM-101 in the phase I/II BEACON study for SCD. Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. Data from multiple patients in the study is expected in the second half of 2024.
BEAM is also advancing its engineered stem cell antibody paired evasion conditioning strategy to face the toxicity challenges of autologous transplant in SCD and beta-thalassemia patients.
Both SCD and beta-thalassemia have a significant unmet medical need, and if successfully developed and commercialized, BEAM-101 can significantly boost the company&#39;s prospects.
Shares of Beam Therapeutics have plunged 11.9% year to date compared with the industry&#39;s&nbsp; 6.2% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/49/71118.jpg?v=2113437290" />
Image Source: Zacks Investment Research
Other Pipeline Candidates Progressing Well: Apart from hemoglobinopathy candidates, Beam is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302.
The company is developing an in vivo base editor, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (&quot;AATD&quot;), an inherited genetic disorder that can cause early onset of emphysema and liver disease. In June 2024, BEAM dosed the first patient in the phase I/II study to evaluate BEAM-302 for the treatment of AATD. The study is designed to identify the optimal dosage of BEAM-302.
The company will file an investigational new drug (&quot;IND&quot;) application with the FDA to begin clinical studies on BEAM-302 in the United States shortly.
BEAM is also planning to initiate a clinical study on BEAM-301 for the treatment of glycogen storage disease 1a in the United States. An IND application for BEAM-301 is expected to be filed shortly.
Successful development and potential approval for these candidates will be a huge boost for the company.
Encouraging Collaboration Deals: BEAM has established partnerships that allow collaborators to access its editing and delivery technologies.
In October 2023, the company entered into a transfer agreement with Eli Lilly, under which Lilly acquired certain assets and other rights under the Verve Agreement. Following this, Beam received an upfront payment of $200 million as well as a $50 million equity investment from Lilly.
In late 2021, Beam entered into a deal with Pfizer, focused on in vivo base-editing programs for three pre-specified targets for rare genetic diseases. The company will conduct research activities until the selection of a development candidate, after which Pfizer may opt for exclusive, worldwide licenses for each development candidate and will assume responsibility for all development activities, regulatory approvals and commercialization. In January 2022, Beam received an upfront payment of $300 million from Pfizer.
These partnerships offer financial support and potentially help BEAM accelerate the development of its pipeline candidates.
<h3>Other Stocks to Consider</h3>
Other top-ranked stocks in the healthcare sector are Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) and RAPT Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rapt#NASDAQ">RAPT</a>), each holding a Zacks Rank of 2, at present.
In the past 60 days, the estimate for Adaptive Biotechnologies&#39; 2024 loss per share has narrowed from $1.30 to $1.29 while loss per share estimate for 2025 has narrowed from $1.09 to $1.02. Year to date, ADPT shares have lost 28.5%.
ADPT&#39;s earnings beat estimates in two of the trailing four quarters, met the same once and missed on the remaining occasion, the average surprise being 0.65%.
In the past 60 days, the estimate for RAPT Therapeutics&#39; 2024 loss per share has narrowed from $2.94 to $2.93. Loss per share estimate for 2025 has narrowed from $2.06 to $2.05. Year to date, RAPT shares have lost 86.5%.
RAPT&#39;s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 3.19%.
<a href="https://www.zacks.com/stock/news/2300260/here-s-why-you-should-invest-in-beam-therapeutics-beam-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2300260">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

ADPT

RAPT

Here's Why You Should Invest in Beam Therapeutics Now

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of ...

Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nyxoah (NYXH – Research Report), MultiPlan (MPLN –...

Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on BEAM stock, giving a Hold rating on August 7. Mani Foroohar's rating ...

Beam Therapeutics: Hold Rating with Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gene editing holds substantial promise for treating thousands of diseases &ndash; creating incredible opportunities for gene editing stocks.



It could help treat the <a href="https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/promise-precision-medicine/rare-diseases" target="_blank">7,000 diseases caused by genetic disorders</a>, most of which occur with gene mutation. Or, as noted by the <a href="https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders" target="_blank">Cleveland Clinic</a>, when you have the wrong amount of genetic material. It&rsquo;s even helped address a form of inherited blindness in patients, including children. According to <a href="https://www.pennmedicine.org/news/news-releases/2024/may/gene-editing-improves-sight-in-children-treated-for-blindness" target="_blank">Penn Medicine News</a>, &ldquo;nearly half reported measurable improvements in sight, including the two children according to the study.&rdquo;



As <a href="https://www.precedenceresearch.com/gene-editing-market#" target="_blank">noted</a> by Precedence Research, all of these factors could help create a potential $29.93 billion market by 2032, based on today&rsquo;s $6.94 billion valuation.



Look at CRISPR Therapeutics (NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/crsp-stock-quote/">CRSP</a>), for example.



Months ago, the company&nbsp;received U.S. FDA approval for its sickle-cell treatment and clearance for its treatment of transfusion-dependent beta-thalassemia (TDT).&nbsp;While CRISPR is still one of the top gene editing stocks to buy, there are others with just as much promise.



<h2>Intellia Therapeutics (NTLA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/ntla-stock-300x169.jpg" alt="Intellia Therapeutics (NTLA Stock) logo on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>Look at Intellia Therapeutics (NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/ntla-stock-quote/">NTLA</a>), for example.



Just weeks ago, the company reported <a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-positive-long-term-data-ongoing" target="_blank">positive long-term data</a> from a Phase 1 study of NTLA-2002 for treating hereditary angioedema (HAE), which impacts one in 50,000 people.



According to the company, a single dose led to a <a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-positive-long-term-data-ongoing" target="_blank">98% mean reduction</a> in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease.



The company expects to report Phase 2 results this year and start Phase 3 trials this year.



The company also received authorization from the &ldquo;United Kingdom&rsquo;s Medicine and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease,&rdquo; <a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-receives-authorization-initiate-phase-12-0" target="_blank">as noted in a recent press release</a>.



<h2>Beam Therapeutics (BEAM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/genetics-dna-flgt-1600-300x169.jpg" alt="a visualization of DNA in a vial. TSHA stock"><div>Source: Connect world / Shutterstock.com</div></div>There&rsquo;s Beam Therapeutics (NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/beam-stock-quote/">BEAM</a>), which develops BEAM-101 for sickle cell and beta-thalassemia; BEAM-302 for the treatment of severe alpha-1 antitrypsin deficiency; and BEAM-201 for refractory T-cell acute lymphoblastic leukemia / T-cell lymphoblastic lymphoma.



In addition, <a href="https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-h-c-wainwright" target="_blank">analysts at H.C. Wainwright</a> just initiated a buy rating on the BEAM stock with an $80 price target. The firm highlighted BEAM&rsquo;s base editing as a key catalyst.



&ldquo;The firm argued that base editing, which has yet to be clinically validated for human therapeutic use, can address the challenges of existing approaches&nbsp;and expand&nbsp;the potential of gene therapies,&rdquo; <a href="https://www.msn.com/en-us/money/markets/beam-therapeutics-gains-as-h-c-wainwright-starts-at-buy/ar-BB1quReD?ocid=BingNewsVerp" target="_blank">as noted by SeekingAlpha</a>.



H.C. Wainwright also believes BEAM&rsquo;s first-in-human data for sickle cell disease this year could &ldquo;further validate BEAM&rsquo;s pipeline.&rdquo;



And while earnings haven&rsquo;t been anything to write home about just yet, that should change with successful trial results. In its most recent quarter, the company posted a <a href="https://www.nasdaq.com/articles/beam-therapeutics-beam-q2-earnings-beat-revenues-miss#:~:text=Beam%20Therapeutics%20Inc.,in%20the%20year-ago%20quarter.">Q2 earnings per share loss of $1.11</a>, which beat by a penny. Revenue of $11.77 million also missed by $1.28 million.



<h2>Global X Genomics &amp; Biotechnology ETF (GNOM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/gene-edit-300x169.png" alt="An image of a scientist holding forceps, taking a piece of a DNA helix"><div>Source: Panuwach/Shutterstock</div></div>Or, if you want to diversify with most gene-editing stocks at a low cost, there&rsquo;s the&nbsp;Global X Genomics &amp; Biotechnology ETF&nbsp;(NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/gnom-stock-quote/">GNOM</a>).



GlobalXETFs.com notes that the exchange-traded fund (ETF) has <a href="https://www.globalxetfs.com/funds/gnom/" target="_blank">an expense ratio of 0.50%</a> and holds 41 stocks that could benefit from&nbsp;gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.



Some of its top holdings include CRISPR Therapeutics,&nbsp;Illumina&nbsp;(NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/ilmn-stock-quote/">ILMN</a>), and&nbsp;10X Genomics (NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>).



On the date of publication, Ian Cooper&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/3-gene-editing-stocks-with-potential-to-transform-medicine/">3 Gene Editing Stocks with Potential to Transform Medicine</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Gene Editing Stocks with Potential to Transform Medicine

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beam Therapeutics (BEAM – Research Report) and Taysh...

Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Beam Therapeutics (BEAM – Research Report), with a pri...

Optimistic Outlook on Beam Therapeutics: Advancements and Potential in Precision Genetic Medicines

Beam Therapeutics (BEAM) has received a new Hold rating, initiated by JonesTrading analyst, Soumit Roy. Soumit Roy has given his Hold rating due to...

Hold Rating on Beam Therapeutics Amid Competitive Pressure and Absence of Clinical Data

RBC Capital analyst Luca Issi maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $27.00. The co...

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

CRISPR Therapeutics ($CRSP), based in Switzerland, commands a lofty valuation when assessing near-term metrics, but the profit opportunity is consi...

CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts

BLUE

CRSP

GNOM

MPLN

NTLA

NYXH

TSHA

VRTX

Press Releases

2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Comments

Beam Therapeutics

Vendite allo scoperto

Beam Therapeutics (NASDAQ:BEAM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO